In the world of medical weight management, few treatments have generated as much excitement as Mounjaro (tirzepatide). As a board-certified, fellowship-trained surgeon, I have witnessed firsthand the transformative power of this medication when integrated into a comprehensive, medically supervised weight loss program. Patients often come to us with a critical question: “How much weight can I really expect to lose?”
The answer, as with any medical treatment, is not a simple number. It depends on several factors, including your starting weight, the dose you are on, and your commitment to a healthy diet and exercise regimen. However, we can look to the robust data from clinical trials to provide a clear and realistic picture of what’s possible
Mounjaro, the brand name for tirzepatide, is an innovative medication that works as a dual GIP and GLP-1 receptor agonist. In simple terms, it mimics two hormones that are naturally released after you eat. This dual action helps to regulate blood sugar, decrease appetite, and reduce cravings, leading to a significant reduction in food intake.
The effectiveness of tirzepatide has been extensively studied in a series of clinical trials known as SURMOUNT. The results have been nothing short of remarkable, with patients achieving a level of weight loss previously seen only with bariatric surgery
Here’s a breakdown of the typical weight loss percentages observed in these trials:
15 mg Dose (the highest): Patients on this dose lost an average of 20.9% of their starting body weight over 72 weeks. For a person starting at 250 pounds, this would translate to a loss of over 52 pounds.
10 mg Dose: Patients on the 10 mg dose achieved an average weight loss of 19.5% of their starting body weight. A 250-pound person could expect to lose nearly 49 pounds.
5 mg Dose: At the lower maintenance dose of 5 mg, patients saw an average weight loss of 15% of their starting body weight, or about 37 pounds for a 250-pound individual
In these studies, participants on a placebo, following the same diet and exercise recommendations, lost only about 3% of their body weight, highlighting the profound effect of the medication itself. These statistics provide a strong foundation for setting realistic expectations and demonstrate that tirzepatide is a powerful tool for chronic weight management
Results vary based on dose, lifestyle, and individual response.
While the numbers from clinical trials are inspiring, it’s important to understand that Mounjaro and its weight loss-specific version, Zepbound, are not a “quick fix.” The most successful outcomes are achieved when the medication is part of a comprehensive, medically supervised program.
This is where a board-certified surgeon like myself and a dedicated team become invaluable. Our medical weight management program at Miami Bariatric and Plastic Surgery MD provides:
As a fellowship-trained surgeon with over a decade of experience, I oversee your treatment from start to finish. This ensures your safety and a customized approach to maximize results while minimizing side effects.
Mounjaro’s dosing starts low (2.5 mg) and increases gradually every four weeks under medical guidance. This steady process is key to helping your body adjust and finding the most effective dose with the fewest side effects.
Our program is more than just a prescription. We provide personalized nutritional guidance, regular check-ins, and a supportive environment to help you build and maintain healthy habits for long-term success.
The benefits of Mounjaro extend far beyond weight loss alone. Clinical studies have also shown significant improvements in:
In my practice, I have seen patients not only lose weight but also reduce their dependence on other medications for conditions like type 2 diabetes and high blood pressure. This is the true measure of success.
If you are ready to explore whether Mounjaro or Zepbound is the right option for you, I invite you to schedule a consultation with us at Miami Bariatric And Plastic Surgery MD. Together, we can create a personalized plan to help you achieve your health goals and reclaim your life.
Q: How does Mounjaro differ from other weight loss injections like Ozempic? A: Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, making it the first and only medication of its kind. Ozempic (semaglutide) is a single GLP-1 agonist. The dual action of Mounjaro has demonstrated a greater average weight loss in clinical trials, giving it a significant advantage in many cases.
Q: Is Mounjaro a surgical option? A: No, Mounjaro is a medical weight loss medication that is administered via a weekly injection. It is part of our comprehensive medical weight management program and is not a surgical procedure.
Q: Who is a good candidate for medical weight loss with Mounjaro? A: Mounjaro is FDA-approved for adults with type 2 diabetes and is also used for weight management under the brand name Zepbound. Good candidates are typically those with a BMI of 30 kg/m2 or higher, or a BMI of 27 kg/m2 with a weight-related health condition, who are committed to a supervised program of diet and exercise.
Q: How do I get started with a medical weight loss program? A: The first step is to schedule a consultation with our office. We will conduct a thorough medical evaluation, discuss your health history and goals, and determine if Mounjaro or another medical weight loss approach is the best fit for you. We also provide complete assistance with insurance verification.
Disclaimer:
This information is for educational purposes only and is not intended as medical advice. Mounjaro (Tirzepatide) is a prescription medication that should only be used under the supervision of a licensed healthcare provider. Individual results may vary. Always consult with your doctor before starting any new medication or weight loss program. Insurance coverage for weight loss uses may vary by plan and medical necessity. This content does not guarantee coverage or outcomes.
Clinical Trial Data (SURMOUNT-1): The data on weight loss percentages for Mounjaro (tirzepatide) was sourced from the SURMOUNT-1 clinical trial, which studied the medication’s effects in adults with obesity or overweight without diabetes. This information is crucial for setting realistic expectations.
Drug Information and Safety: Details about Mounjaro’s dosage, mechanism of action, and potential side effects were drawn from comprehensive medical reference sites.
Dr. Terushkin’s Professional Background: To establish Dr. Terushkin’s expertise, the blog post referenced his credentials, including his education, board certifications, and fellowship training.
Clinic and Service Information: Details about the services offered at the Florida Surgery & Weight Loss Center, including medical weight management and other surgical options, were used to provide a complete picture of the practice’s offerings.
⚖️ Regulatory & Safety Disclosure
FDA Status: Compounded Semaglutide and Tirzepatide are not FDA-approved. These are distinct, customized preparations and are not “generic” versions of Ozempic®, Wegovy®, or Mounjaro®. The FDA does not review compounded drugs for safety, effectiveness, or quality.
Sourcing: We utilize only FDA-registered 503B outsourcing facilities to ensure pharmaceutical-grade purity. Compounding is utilized to meet specific clinical needs or during documented national drug shortages.
Safety Warning: GLP-1 therapies require medical supervision. Potential risks include nausea, vomiting, and diarrhea. Serious risks include pancreatitis and a potential risk of thyroid C-cell tumors. Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
Real people, REAL RESULTS! Check out a few of the many people that we have helped reach their ideal weight goals over the years.
